July, 2026 - nextgenmedtech.in

Streamlining MDR Compliance: New Clinical Investigation Exemptions for 2026 REGULATORY UPDATE · EU MEDICAL DEVICE REGULATION Streamlining MDR Compliance: New Clinical Investigation Exemptions for 2026 Commission Delegated Regulation (EU) 2026/1451 expands the list of implantable and Class III devices exempted from clinical investigations under the MDR — here's what changed, and what manufacturers still have to do. In force: 19 July 2026 Published: 29 June 2026 Amends MDR Art. 61(6)(b) The European medical device landscape has just shifted. With the publication of Commission Delegated Regulation (EU) 2026/1451, the European Commission has officially expanded the list of implantable and Class III devices exempted from the obligation to perform clinical investigations. This amendment to the Medical Device Regulation (MDR) 2017/745 is a pragmatic step toward reducing the investigative burden for technologies the Commission now classifies as “well-established.” EU Official source: Commission Delegated Regulation (EU) 2026/1451 Published in the Official Journal of the European Union, L series, on 29 June 2026 (ELI: 2026/1451/oj). Read the official text on EUR-Lex → What Makes a Device “Well-Established”? The decision to exempt certain high-risk devices was not made lightly. Following a wide consultation with the Medical Device Coordination Group (MDCG), the Commission identified specific technologies that meet a high bar for clinical history and stability. To qualify for these exemptions under the new regulation, a device type must demonstrate: 01 Simple & Stable Design A common architectural framework that has not seen radical changes over time. 02 Proven Safety Track Record A long history on the Union market without being associated with past safety issues. 03 Known Performance Well-known clinical performance characteristics, where the technology is considered the standard of care. 04 Mature Indications Little to no evolution in clinical indications or the current state of the art. Which Devices Are Now Exempt? Article 1 of the new regulation replaces the previous list in Article 61(6), point (b) of the MDR with a significantly more comprehensive directory, grouped below by clinical field for readability. Dental & Orthodontic Established list Dental implants Orthodontic devices Dental fillings Dental braces Tooth crowns Dental barriers Dental veneers Transpalatal distractors Fixation, Fasteners & Structural Implants Established list Sutures Staples Screws Wedges Plates Wires Pins Clips Connectors Nails Anchors Spinal posterior fixations Bone tacks Bone wax Bone fillers Bone substitutes Stem centralisers Diaphyseal obturators Textile braids Fixation and connector tools Catheters, Tubes & Vascular Access New additions Atrioseptostomy balloon catheters Catheters coated with anticoagulants Port catheters Port plugs Introducers Dilators Catheter passers Feeding tubes Gastrostomy buttons Blood bags incorporating anticoagulants Guidewires Pressure wires Surgical & Neurosurgical Instruments New additions Cranial perforators Cranio-blades Ventricular drains Reusable surgical instruments Springs for skull enlargement Patties and strips Stylets and stylet guides Needles Needle holders Forceps Cannulas Snares Suture Accessories & Ligation New additions Suture pledgets Suture sleeves Suture buttons Fiber ligatures Tubal extraluminal ligation devices Suspensory fixations and cinches Cardiac & Electrophysiology New additions Magnets for implantable pulse generators Pacing wires and leads Lead caps Endovascular embolisation coils Embolisation particles Cables Shunts Internal defibrillation paddles Imaging & Radiographic Markers New additions Radiography markers Note: this list reflects the categorisation used in this article for readability; the legal text itself (Article 1) presents the devices as a single, undivided list under Article 61(6), point (b) of the MDR. The Catch: Clinical Evaluation Is Still Mandatory It is vital for manufacturers to understand that an exemption from clinical investigations is not a total exemption from clinical oversight. Recital 5 — Regulation (EU) 2026/1451 Manufacturers of the exempt devices listed above are still required to plan, conduct, and document a clinical evaluation in accordance with Article 61 of Regulation (EU) 2017/745. This evaluation must be based on sufficient clinical data and remain in compliance with any relevant product-specific Common Specifications (CS) that may be available. Looking Ahead Regulation (EU) 2026/1451 was published in the Official Journal on 29 June 2026 and entered into force on the twentieth day following publication — 19 July 2026. 20 Mar 2026 Regulation adopted 29 Jun 2026 Published in Official Journal 19 Jul 2026 Entered into force For manufacturers of the newly listed devices, this update provides a clearer pathway to market by acknowledging the maturity of their technologies. However, the requirement for robust clinical evaluation remains the cornerstone of ensuring patient safety in the European Union. Watch: Understanding the Update A closer look at the regulation and its practical impact on clinical strategy. Official text: Commission Delegated Regulation (EU) 2026/1451 — EUR-Lex This article is for general informational purposes and does not constitute regulatory or legal advice.

Month: July 2026

EU Regulation 2026/1451: New Clinical Investigation Exemptions for Medical Devices

The EU MDR Timeline

FDA TAP Program (TPLC Advisory Program)